ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.Ontario health technology assessment series · 2022Trial
- Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use ofScientific reports · 2021Trial
- Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.The Journal of clinical investigation · 2020Trial
- Precision medicine in thyroid nodules: current strategies, challenges, and future directions.Hormones (Athens, Greece) · 2026Review
- Article
- Extraction and dual-phase optimization of anticancer doses of selective novel flavonoids from yangmei (3 Biotech · 2025Article
- Article
- Epigenomic profiling of papillary thyroid carcinoma reveals distinct subtypes with clinical implications.NPJ precision oncology · 2025Article
- Article
- Epigenetics in thyroid cancer: a bibliometric analysis.Endocrine connections · 2024Article
- Exploring prognostic DNA methylation genes in bladder cancer: a comprehensive analysis.Discover oncology · 2024Article
- Neural-net-based cell deconvolution from DNA methylation reveals tumor microenvironment associated with cancer prognosis.NAR cancer · 2024Article
- Causal relationship between gut microbiota and thyroid nodules: a bidirectional two-sample Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated ccRCC.Molecular diagnosis & therapy · 2023Article
- Association of DNA Promoter Methylation andCurrent oncology (Toronto, Ont.) · 2023Article
- A Retrospective Evaluation of the Diagnostic Performance of an Interdependent Pairwise MicroRNA Expression Analysis with a Mutation Panel in Indeterminate Thyroid Nodules.Thyroid : official journal of the American Thyroid Association · 2022Article
- Genome-wide DNA methylation profiling and identification of potential pan-cancer and tumor-specific biomarkers.Molecular oncology · 2022Article
- Histone acetylation modifications: A potential targets for the diagnosis and treatment of papillary thyroid cancer.Frontiers in oncology · 2022Review
- DNA repair proteins may differentiate papillary thyroid cancer from chronic lymphocytic thyroiditis and nodular colloidal goiter.Scientific reports · 2021Article
- Genome-Wide Histone H3K27 Acetylation Profiling Identified Genes Correlated With Prognosis in Papillary Thyroid Carcinoma.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThyroid cancer is frequently difficult to diagnose due to an overlap of cytologic features between malignant and benign nodules. This overlap leads to unnecessary removal of the thyroid in patients without cancer. While providing some improvement over cytopathologic diagnostics, molecular methods frequently fail to provide a correct diagnosis for thyroid nodules. These approaches are based on the difference between cancer and adjacent thyroid tissue and assume that adjacent tissues are the same as benign nodules. However, in contrast to adjacent tissues, benign thyroid nodules can contain genetic alterations that can be found in cancer.
resultsBy conducting reduced representation bisulfite sequencing in 109 thyroid specimens, we found significant differences between adjacent tissue, benign nodules, and cancer. These tissue-specific signatures are strongly linked to active enhancers and cancer-associated genes. Based on these signatures, we developed a new epigenetic approach for thyroid diagnostics. According to the validation cohort, our test has an estimated specificity of 97% [95% confidence interval (CI), 81-100], sensitivity of 100% (95% CI, 87-100), positive predictive value of 97% (95% CI, 83-100), and negative predictive value of 100% (95% CI, 86-100).
conclusionsThese data show that epigenetic testing can provide outstanding diagnostic accuracy for thyroid nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.